Clinical trial
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic…
NCT00290810 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00290810 |
|---|---|
| Title | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Enrollment | 12 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Aug 1, 2010 |
| First posted | Feb 13, 2006 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: